patienthistory

152 results found.

Top Stocks matching your search for "patient history"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 17, 2023

It can be shown that treatment bringing back indep... See more

Feb, 16, 2023

$AVXL This may show why Anavex is definitely on th... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementi... See more

Feb, 1, 2023

This will bring in billions of revenue and it will... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
PALI

Palisade Bio Inc

-19.56%

$2.25 - $1.81

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 1, 2023

$PALI patients ⏰⏰⏰

Jan, 23, 2023

$PALI patients are in high gear 🤑🤑🤑

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 17, 2023

It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

Feb, 16, 2023

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Feb, 16, 2023

Pill = best possible treatment course.

Feb, 14, 2023

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Jan, 24, 2023

Half the patients improved over baseline over 1 year.

Jan, 24, 2023

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

Jan, 22, 2023

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

Jan, 18, 2023

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Jan, 17, 2023

Anavex has over 760 patients that have taken it without any significant issues. .

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Feb, 1, 2023

This will bring in billions of revenue and it will make the life quality longer for AD patients.

Jan, 29, 2023

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

Jan, 18, 2023

CURING LEUKEMIA isn't a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

Jan, 11, 2023

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

Jan, 9, 2023

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

Jan, 6, 2023

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

Dec, 30, 2022

but mostly new hope for all the families and patients with AZ.

Dec, 29, 2022

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

PALI

Palisade Bio Inc

-19.56%

$2.25 - $1.81

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 1, 2023

$PALI patients ⏰⏰⏰

Jan, 23, 2023

$PALI patients are in high gear 🤑🤑🤑

Oct, 5, 2022

Conclusion: For patients undergoing elective bowel resection surgery, LB1148 was safe and well-tolerated and significantly accelerated the return of bowel function.